SnagRx review

Take a quarter dose here and you pay what a full dose costs. SnagRx says "Same price no matter the dose" in its running header, in its plan bullets and in its hero — there is no ambiguity to exploit, and no low-dose product to move to. Credit for the part that matters most: it publishes the whole billing-cycle table, one, three, six and twelve months side by side, so the standing rate is recoverable rather than buried behind the cheap one. It also names the two states it cannot serve and gives the regulatory reason. Three things will cost you. The figure splashed across the homepage is the twelve-month rate, and month to month is well over 40% higher on semaglutide. The countdown labeled "Price increases in" is served already at zero. And its published tirzepatide protocol carries garbled units at a starting figure far above the standard one — worth querying before you inject anything.

Vs median

$70/mo below the $169 median across the 242 of 373 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Same price at every dose

Consult

Included in the price

Dietitian

Not included

Labs

Not required

Pricing

Flat at every dose

Price last updated

August 2026

SnagRx does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

SnagRx sells compounded semaglutide and compounded tirzepatide as a monthly plan at one rate per molecule, with the discount tied to the length of term you commit to rather than to the dose you take. It publishes the whole billing-cycle table — one, three, six and twelve months side by side, under a heading of that name — which is what makes the true month-to-month rate recoverable rather than hidden behind the cheapest rung. Its dose basis is stated repeatedly and unambiguously: "Same price no matter the dose." It explains the 503A framework accurately, including USP 795/797 and state board licensure, without naming a pharmacy, and it names the two states it cannot serve and the regulatory reason.

ONE PRICE AT EVERY DOSE. A patient holding at a quarter dose pays exactly what a full-dose patient pays, and no low-dose product is published to move to instead

• The $69/month splashed across the homepage is the twelve-month prepay rate. Month to month is $99 — 43% higher. Tirzepatide is advertised at $119 against $149 month to month
• The homepage countdown labeled "Price increases in" is served with its digits already at 00: 00: 00: 00
• The published tirzepatide protocol reads "10/mg for the first 4 weeks / 20/mg for the next 8 weeks" — the units are garbled, and 10 mg a week would be an unusually high start against a standard compounded starting dose of 2.5 mg
• Three mutually inconsistent discount claims run across two pages: "Was $299", "Summer Start Promo Applied. Save $230 Every Month" and "Get $450 OFF your prescription instantly and lock in that pricing!"
• "GLP-1 with Locked-In Flat Pricing for Life" is the homepage headline, but the only thing the pricing table locks is the term you commit to
• No compounding pharmacy is named — only "U.S.-based 503A compounding pharmacies" — and no full state list is published
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

SnagRx is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• What microdosing GLP-1 costs
• Low dose vs full dose
• What a flat price costs at a low dose
• The true annual cost of a plan